Compare Novartis AG (NVS) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Vanguard International High Dividend Yield ETF — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Vanguard International High Dividend Yield ETF trades at $101.33. The key difference: Novartis AG pays a 3.17% dividend while Vanguard International High Dividend Yield ETF pays none, and Vanguard International High Dividend Yield ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | VYMI | |
|---|---|---|
Market Cap | $290.25B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $168.62 | $101.60 |
52-Week Low | $113.50 | $79.95 |
Enterprise Value | $330.27B | — |
Dividend Yield | 3.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
VYMI trades at $100.23, down 0.65% with a bullish technical signal from moving averages while oscillators remain neutral. The ETF offers international high dividend yield exposure with over 1,500 stocks and has delivered 10.8% annualized returns over 10 years. Recent institutional buying by D.A. Davidson & CO. increased their position by 265.6% during the latest quarter.
VYMI presents a compelling international diversification opportunity with strong dividend growth potential, though currency fluctuations and global economic conditions pose risks. The ETF's low 0.07% expense ratio and broad diversification across developed and emerging markets provide defensive characteristics in uncertain market environments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
